Acropolis Investment Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 333.4% during the 4th quarter, HoldingsChannel reports. The fund owned 9,032 shares of the biopharmaceutical company’s stock after acquiring an additional 6,948 shares during the period. Acropolis Investment Management LLC’s holdings in Pfizer were worth $327,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer during the second quarter worth $103,000. Herndon Capital Management LLC acquired a new position in Pfizer during the second quarter worth $120,000. Americafirst Capital Management LLC acquired a new position in Pfizer during the third quarter worth $127,000. Private Vista LLC raised its holdings in Pfizer by 2,277.3% during the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 190,933 shares during the last quarter. Finally, Lipe & Dalton raised its holdings in Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares during the last quarter. 70.43% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE PFE) opened at $36.77 on Friday. The firm has a market cap of $218,890.00, a PE ratio of 21.01, a P/E/G ratio of 2.06 and a beta of 0.91. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.70%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is presently 77.71%.
Pfizer declared that its board has authorized a stock buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.
Several research analysts have weighed in on PFE shares. UBS Group set a $40.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Sanford C. Bernstein set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a report on Wednesday, January 17th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price for the company in a report on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $39.40.
In related news, Director W Don Cornwell sold 1,758 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $36,790. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Charles H. Hill sold 42,393 shares of the stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 115,765 shares of company stock valued at $4,217,653. 0.06% of the stock is owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.